Silence Therapeutics plc (ADR)
General ticker "SLN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $300.3M (TTM average)
Silence Therapeutics plc (ADR) follows the US Stock Market performance with the rate: 48.3%.
Estimated limits based on current volatility of 3.4%: low 12.01$, high 12.86$
Factors to consider:
- Total employees count: 88 (-24.1%) as of 2025
- Top business risk factors: Need additional capital, No approved products, Sirna development failure, Third-party risks, Regulatory and compliance
- Current price 27.5% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.56$, 9.96$]
- 2026-12-31 to 2027-12-31 estimated range: [3.21$, 9.02$]
Financial Metrics affecting the SLN estimates:
- Negative: with PPE of -3.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Positive: 42.26 < Shareholder equity ratio, % of 47.40 <= 49.86
- Negative: 0 < Industry inventory ratio change (median), % of 0
Short-term SLN quotes
Long-term SLN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | £25.38MM | £43.26MM | £0.56MM |
| Operating Expenses | £74.98MM | £106.58MM | £91.64MM |
| Operating Income | £-49.60MM | £-63.32MM | £-91.08MM |
| Non-Operating Income | £-0.71MM | £18.86MM | £2.48MM |
| Interest Expense | £0.03MM | £0.00MM | £0.00MM |
| R&D Expense | £44.02MM | £67.88MM | £67.75MM |
| Income(Loss) | £-50.31MM | £-44.46MM | £-88.60MM |
| Taxes | £-7.04MM | £0.84MM | £0.01MM |
| Net Income(Loss)* | £-43.27MM | £-45.31MM | £-88.61MM |
| Stockholders Equity | £21.99MM | £134.02MM | £62.30MM |
| Assets | £119.45MM | £202.63MM | £131.44MM |
| Operating Cash Flow | £-39.35MM | £-54.05MM | £-62.27MM |
| Capital expenditure | £0.04MM | £0.17MM | £0.06MM |
| Investing Cash Flow | £16.43MM | £-17.55MM | £-47.99MM |
| Financing Cash Flow | £25.16MM | £113.54MM | £0.01MM |
| Earnings Per Share** | £-3.50 | £-2.94 | £-5.63 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.